GK

Gurvinderpal Kaur

Active Director Director DIN 07362925
DIN 07362925 First appointment Mar 2016 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2016
Shareholding value •••• Premium profile

About Gurvinderpal Kaur

Data last updated:

Gurvinderpal Kaur is a Director at Dazroz Pharmaceuticals Private Limited (since 2016). The company operates in Pharma. Dazroz Pharmaceuticals Private Limited reported revenue of ₹54.7 Lakh (FY 2024).

DIN 07362925
Primary Designation Director
Industry Pharma
First Appointment 21 Mar 2016
Oldest Company Age 10 yrs
Largest company Dazroz Pharmaceuticals Private Limited · ₹54.7 Lakh (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director21 Mar 20162016₹54.7 Lakh (FY 2024)Active

Board colleagues of Gurvinderpal Kaur

Directorship timeline

Open interactive timeline →
Dazroz Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Gurvinderpal Kaur

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Gurvinderpal Kaur

Gurvinderpal Kaur currently holds 1 directorship: Dazroz Pharmaceuticals Private Limited (Director, since 21 Mar 2016, revenue ₹54.7 Lakh (FY 2024)).

Gurvinderpal Kaur was first appointed on 21 Mar 2016 as Director at Dazroz Pharmaceuticals Private Limited.

The current boards of Gurvinderpal Kaur's companies include Pritpalsingh Harjindersingh Sundhuria (Dazroz Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available